Search Prime Grants

R01AG074502

Project Grant

Overview

Grant Description
Determining the Context Specificity of Metformin Treatment on Muscle Mitochondria and Healthspan - Summary

Metformin, the most widely prescribed medication for treating type 2 diabetes, is increasingly recognized for its healthspan effects that resemble exercise. The beneficial effects of metformin, like aerobic exercise, appear to be mediated through an energetic and/or redox stress mechanism, raising the prospect that the two approaches could exert additive or even synergistic effects.

Surprisingly, our recently published clinical trial showed that metformin inhibits the beneficial effects of aerobic exercise training (AET) on skeletal muscle mitochondrial function and whole-body insulin sensitivity. Interestingly, subjects who entered the study with the highest mitochondrial complex I supported OXPHOS function and insulin sensitivity were the most negatively affected by metformin treatment. How metformin inhibits the positive effects of AET, why this effect is most pronounced in those with the highest mitochondrial function, and how these interactions ultimately impact healthspan and lifespan are unknown.

The hypothesis of this proposal is that the effects of metformin on healthspan and lifespan are context specific; beneficial in the context of low energy demand/mitochondrial capacity but detrimental in the context of high energy demand/mitochondrial capacity. To test this hypothesis, the study will leverage a rat model with divergent selection for intrinsic aerobic capacity, referred to as high capacity and low capacity runners (HCR/LCR). By selecting for maximal treadmill running capacity, LCR and HCR rats diverged in intrinsic mitochondrial function, lifespan, and metabolic traits that increase or decrease the risk for chronic disease.

Changes in mitochondrial function will be assessed using ex vivo respirometry that measures the interplay among three thermodynamic forces. Further, the proposal uses targeted kinetic and quantitative mitochondrial proteomics to understand appropriate or aberrant cellular remodeling, and novel in vivo imaging approaches to understand changes in mitochondrial morphology and dynamics.

The specific aims are to:
1) Establish if mitochondrial changes to metformin treatment are context specific,
2) Establish if the effects of metformin on adaptations to aerobic exercise training are context specific, and
3) Determine whether the beneficial effects of metformin on healthspan and lifespan are context specific.

It is expected that with metformin treatment, remodeling of mitochondria will be consistent with improved outcomes in LCR rats, but have no effect or will be detrimental in HCR, with or without exercise training. Further, it is expected that metformin will extend healthspan and lifespan in LCR rats, but not HCR rats.

Successful completion of these aims will reveal the importance of context specificity on metformin action and the mechanisms underlying its positive and potentially negative impacts on healthspan and lifespan. This information is critical given the ever-expanding off-target use of metformin in healthy individuals without chronic disease and/or overt metabolic dysfunction. Results from this project will help inform who can benefit from metformin treatment, and more importantly, who should avoid it.
Funding Goals
TO ENCOURAGE BIOMEDICAL, SOCIAL, AND BEHAVIORAL RESEARCH AND RESEARCH TRAINING DIRECTED TOWARD GREATER UNDERSTANDING OF THE AGING PROCESS AND THE DISEASES, SPECIAL PROBLEMS, AND NEEDS OF PEOPLE AS THEY AGE. THE NATIONAL INSTITUTE ON AGING HAS ESTABLISHED PROGRAMS TO PURSUE THESE GOALS. THE DIVISION OF AGING BIOLOGY EMPHASIZES UNDERSTANDING THE BASIC BIOLOGICAL PROCESSES OF AGING. THE DIVISION OF GERIATRICS AND CLINICAL GERONTOLOGY SUPPORTS RESEARCH TO IMPROVE THE ABILITIES OF HEALTH CARE PRACTITIONERS TO RESPOND TO THE DISEASES AND OTHER CLINICAL PROBLEMS OF OLDER PEOPLE. THE DIVISION OF BEHAVIORAL AND SOCIAL RESEARCH SUPPORTS RESEARCH THAT WILL LEAD TO GREATER UNDERSTANDING OF THE SOCIAL, CULTURAL, ECONOMIC AND PSYCHOLOGICAL FACTORS THAT AFFECT BOTH THE PROCESS OF GROWING OLD AND THE PLACE OF OLDER PEOPLE IN SOCIETY. THE DIVISION OF NEUROSCIENCE FOSTERS RESEARCH CONCERNED WITH THE AGE-RELATED CHANGES IN THE NERVOUS SYSTEM AS WELL AS THE RELATED SENSORY, PERCEPTUAL, AND COGNITIVE PROCESSES ASSOCIATED WITH AGING AND HAS A SPECIAL EMPHASIS ON ALZHEIMER'S DISEASE. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Grant Program (CFDA)
Place of Performance
Oklahoma City, Oklahoma 731045005 United States
Geographic Scope
Single Zip Code
Analysis Notes
Amendment Since initial award the total obligations have increased 368% from $651,808 to $3,047,633.
Oklahoma Medical Research Foundation was awarded Context-Specific Metformin Effects on Muscle Mitochondria Project Grant R01AG074502 worth $3,047,633 from National Institute on Aging in April 2022 with work to be completed primarily in Oklahoma City Oklahoma United States. The grant has a duration of 4 years 8 months and was awarded through assistance program 93.866 Aging Research. The Project Grant was awarded through grant opportunity NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).

Status
(Ongoing)

Last Modified 3/5/26

Period of Performance
4/1/22
Start Date
12/31/26
End Date
85.0% Complete

Funding Split
$3.0M
Federal Obligation
$0.0
Non-Federal Obligation
$3.0M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to R01AG074502

Subgrant Awards

Disclosed subgrants for R01AG074502

Transaction History

Modifications to R01AG074502

Additional Detail

Award ID FAIN
R01AG074502
SAI Number
R01AG074502-3023924332
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75NN00 NIH National Insitute on Aging
Funding Office
75NN00 NIH National Insitute on Aging
Awardee UEI
NGCNCJ1X6XA4
Awardee CAGE
4X200
Performance District
OK-05
Senators
James Lankford
Markwayne Mullin

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Institute on Aging, National Institutes of Health, Health and Human Services (075-0843) Health research and training Grants, subsidies, and contributions (41.0) $1,266,216 100%
Modified: 3/5/26